Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Raymond Andersen
Provincial Health Services Authority, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Essa Pharma Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
There is a potential for a FCOI to exist between the SFI and the NIH research. Project results may be relevant to ESSA Pharma.
The only changes since the last FCOI report were in the value of Dr. Andersen's FCOIs. The value of his consulting fees increased to (b)(4) per year. His stock value decreased to (b)(4) at the time of reporting. The conditions in Dr. Andersen's management plan have not changed.
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics
Once prostate cancer becomes castration-resistant there are no long-term or curative therapies that can be offered and the patient will succumb to his disease in a few years. There is mounting evidence supporting the concept that development of castration-resistant disease is causally related to molecular changes affecting the androgen receptor that include expression of constitutively active truncated splice variants that lack a C-terminus ligand-binding domain. Here we propose studies to reveal the mechanisms of antagonists of androgen receptor activation function-1 for further development of novel therapeutics that will delay or prevent hormonal progression to the terminal stage of prostate cancer.
Filed on January 31, 2019.
Tell us what you know about Raymond Andersen's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Raymond Andersen”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Raymond Andersen | British Columbia Cancer Agency | Conflict of Interest | Essa Pharma Inc. | >$600,000 |
| Raymond Andersen | Provincial Health Services Authority | Conflict of Interest | Essa Pharma Inc. | >$600,000 |
| Raymond Andersen | Provincial Health Services Authority | Conflict of Interest | Essa Pharma Inc. | $150,000 - $199,999 |
| Raymond Andersen | British Columbia Cancer Agency | Conflict of Interest | Essa Pharma Inc. | $100,000 - $149,999 |
| Raymond Andersen | Provincial Health Services Authority | Conflict of Interest | Essa Pharma Inc. | $150,000 - $199,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.